Related Experiment Video
Updated: May 2, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
CXCL3 is a potential target for breast cancer metastasis
Amanda Lay Pin See, Poh Kuan Chong, Ssu-Yi Lu
1Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, MD6, Centre for Translational Medicine #10-01M, 14 Medical Drive, Singapore 117599. bchlyp@nus.edu.sg.
Abstract:
Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
Insights
Chemokine CXCL3 is upregulated in aggressive breast cancer cells, driving metastasis. Targeting CXCL3 presents a promising therapeutic strategy for breast cancer treatment.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Secreted proteins are crucial targets for cancer drug development.
- Understanding proteins involved in cancer metastasis is key to effective treatment.
Purpose of the Study:
- To identify and characterize novel secreted protein targets in breast cancer metastasis.
- To investigate the role of CXCL3 in the progression and metastasis of breast cancer.
Main Methods:
- Utilized iTRAQ-based tandem mass spectrometry to quantify proteins in breast cancer cell secretomes.
- Employed siRNA and antibody neutralization assays to study CXCL3 function.
- Conducted a meta-analysis of CXCL3 mRNA levels in clinical breast cancer samples.
Main Results:
- CXCL3 was significantly upregulated in highly metastatic breast cancer cell lines.
- CXCL3 inhibition reduced metastatic potential in vitro.
- Elevated CXCL3 mRNA levels correlated with clinical breast cancer progression.
Conclusions:
- CXCL3 plays a functional role in breast cancer metastasis.
- CXCL3 is a potential therapeutic target for combating breast cancer spread.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle

